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- 
6-pF]Fluo pamine is a positron-e ng analogue of 
dopamine. recently reported a for visualizing 
cardiac sympathetic innervation i vivo using positron emis- 
sion tomography (PET) after intravenous injection of 
B-[‘BF]fluorodopamine in 
makes the results of ad 
in humans, focusing on is 
not only for visualizing sites of sympathetic innervation but 
also for assessing aspects of sympathoneural function non- 
invasively. 
The neuronal uptake and intraneuronal disposition of 
fluorocntecholamines are qualieativeiy similar to those of 
endogenous catecholamines (1-5). Preclinical studies using 
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FLI.9OKO.t9OR4MlNE SCANNING IN HUMANS 
enzymes 
ferase, 
monoamim oxidase and catechol-O-methyltrans- 
The present study addressed the following questions: 
1) Can 6.[LsF]duorodopamine be used to visualize the sym- 
pathetic innervation of the myocardium in humans? 2) At 
doses required to visualize the myocardiat innervation 
adequately in humans, what are the hemodynamic effects 
of @$]fluorodopamine, and what is the estimated radia- 
tion dose to the main target organ, the wall of the uri- 
naY 
bladder (IO)? 3) What is the fate of circulating 
$[t FJfhtorodcpamine, and how does this relate to the use 
of ~~‘s~]fluo~do~~m~ne as a sytnpathoneural im ’ 
the effects of treatment with dasipmmme, 
neuronal uptake of catecho~ami~es 
ases yffl~thetic nerve activity (1 I) on 
ocnomical results after ir$iection of
’ sessions were canduwd in 13 hedthy male volunteers 
to 69 years, webht 70 to 100 with their written 
d consent. &*cn~rlg medickl tory, physica! ex- 
amination, electrocardiogram (ECG) and blood and urine 
tests were normal. The study protocol ww approved bythe 
Institute Clinical Research Subpanurds of the National Insti- 
ical Disorders and Stroke, National 
Institute, National Institutes ofHeal 
tew and Ra~~~ti~n Safety Corn 
cathettx was insert 
12.5mm thickness, 5. I-mm apart, pi 
verse sp&l resolution 6.8 fflm). 
fore administntion of
the emission scans for 
continuous monitoring of blood p~ssulr: and for 
mples, a brachid or radial artery catheter 
wss kerQd perCUtaneous]y after anesthesia of the overly- 
@ s&n usnkg kkaine. The catheter was flushed occasion- 
;nu4” with a dilute heparin solution. 
~[“~]~uorodopamine passed quality control testing 
(chemical nd radiochemical purity at !.eFest 
being administered (12). It was dissolved in -10 ml ~1 
normal saline solution and infused by syrkge pump at a 
constant rate: for 3 mia (1 min in one subject), at doses of I 
{one stuayy), 1.5 (one stu y), 2 (two studies), 3 (two stu 
and 4 (nine studies) mCi. 
Continuous PET scanning b 
administration a d ended 2.S to 3 h later. For purposes of 
data analysis, scanni 
The data acquisition was no 
mC~~rno~ at the time of injecti 
10’ molecules ofGF-dopamine 
stable fbtorine-19. 
vesseI containing N-(trifluoroace~ryl)-3,4-dimethoxyd- 
t~i~uo~oacetoxyme~cu~o-beta-~hen~thy~amine (I 10 mg, 
~01, synthesized in the PET Department, National 
itutes of Health) dissolved in 3 ml of acetomttile and 
diluted to 1 I ml with chloroform. The mixture stood for 
S min before transfer through a silica-packed column &-mm 
internal diameter x IlO-mm length, 4.44 g). The reaction 
vessel and column were washed with 10 ml of chloroform. 
The sofvent was evaporated under vacuum, with heat sup- 
plied by a thermostatically controlled oil batb (130 f 10°C). 
For hydrolysis, hydeoiodic acid (47% stabilized with 0.04% 
husphoric acid, 1.6 ml) was added and refluxed at 
130 + 10°C for 10 min. The hydroiodic acid was then 
removed under vacuum and beat using the oil bath and the 
residue dissolved in 2 ml of high performance liquid chro- 
matographic (HPLC) mobile phase (0.1 mot/liter of monoso- 
dium phosphate, 0.01% ascorbic acid, pH 3). The solution 
= 3), 80 pl of the alumina supernate was injiected into a liquid 
chromatographic apparatus c upled to a mu~tjc~a~ne~ efec- 
metabolites using the detector. 
The first void of urine after the PET scanning session was 
injection of 6-[‘BF]fluorodopamine wastransferred into a 
separate, plastic, preweighed receptacle containing -30 ml 
of 6N hydrochloric acid, and the time was recorded. 
few subjects, the radioactivity c#~ce~trat~~~ in the an
.7 min in the achy phase an 
ml) was positively and lines\rly (r = 0.90, p < 0.01) related to
the ~~‘~~~uo~up~ine dose. When expressed as nCi-kg/ 
ocardial radioactivity concentration 
linearly (r = 0.72, p f 0.05) related 
ine c~~centrati~~. 
teau levels within afew minutes after initiation ofthe infksion 
of t$*~uorodopam.ine and then decreased rapidly beginning 
a&r the end gf the infusion. Whereas  &exponential curve fit 
the empiric data well for myocardial Q-[*8FJfluorodopamine- 
derived tioactivity, a triexponential curve was required to fib 
” ‘- 
0 5 '0 !5 20 
TIME (fniriutes) 
the empiric data for 6-I’~F]fiuorodspamin~derivr: 
ity in blood and plasma. The ~~~atio~~ for ihe cu 
were (for blood) y = 21 ,920e-Q.757gt + t ,921e-0*W891 + 
1 2&-0.00792t 
and (for plasma) y = 18,355e’D*5427t + 
5ke-0*W4T’ + 1,933e- 0*QD7? In blood aad plasma, the half-life 
values were therefore 1.4 and I .3 min for the rapid early 
component, 7 and 16 min for the middle component and $8 and 
87 min for the slow late component. Similar triexponential 
curves for radioactivity n blood and plasma were obtained in
desipramine-treated subjects. 
The time-activity curve for plasma di 
blood. During and for a few minutes after the infusion of 
6-[“F]fluorodopamine, theplasma total radioactivity con- 
centration was less than the whole-blood radioactivity con- 
centration i all subjects. The fluorine-l8 concentration in 
whole blood subsequently declined more rapidly than did the 
plasma radioactivity concentration in all subjects, o that he 
two time-activity curves crossed at -10 min. Thereafter, 
the plasma radi~~~t~v~ty exceeded t 
uch less than 1 th 
6-[‘8FJfIuorodopamine co  
mediately after the end of 
1 GOL EIN ET AL. 
met&ok. In the subject with an indwelling Foley catheter 
session, excretion of W-compounds 
asses, with W-dopamine the main 6F 
compound in the first severai minutes, 6~~homova~illi~ acid 
the main compound in subsequent samples during the scan- 
ning session and dI+anillylmandelic a id the main com- 
pound in ahe remainder of the 24-h urine collection. In the 
four subjects with measured excretion rates of catechols and 
~-m~thyl~ted metabolites, 94 t 26% of the imjected com- 
und was exr eted as W-dopamine or metabolites of 6F- 
pamine or 6F-norepinephrine during the 24 h after injec- 
tion of 8-[LRF]Ruorodopamine. 
. Pretreatment with 
oral desipramine markedly a&ted the PET and neurochem- 
ical results. In desipramine-treated subjects, visualization f 
the left ventricular myocardium was invariably poor. During 
and just after 6-[ ‘*F]fluorodopamine administration, myocar- 
was 152 m-in, and the y intercept value was 3,012 nci-kglml- 
mCi in desipramine-treated subjects, in contrast t 
and 4.697 phi-k~ml-mCi in untreated subjects. T
also attenuated by 
(Fig. 6). 
een used successfully to 
visualize cardiac sympathetic innervation i dogs (1). The 
present results show that after intravenous injecti 
6-[ “F]Ruorodopamine  humans, the myocardium is 
eated similarly, with visualization f the left ventricular free 
wall, septum and chamber. 
The percent of injected ~-~“~~~~~r~d~~ami~e taken up 
by the left ventricular myocardium can be estimated, assum- 
ing a normal left ventricular mass of 175 g in a XI-kg adult 
(15) and a tissue density of 1.1 g/ml (16). For a dose of 
0.05 mCi/kg, the peak left ventricular myocardial radioactiv- 
ity concentration was 426nCi/ml, or 968 nCi/kg, correspond- 
m. 
In the isolated, peruse 
(concentration at !4 the maximal 
reaction rate, r spectively) for re 
y neuronal uptake (up&k 
A5 x W” mollg, where 
spend approximately to the k, value for ahe uptake- 
md to <I% of the k, value for the uptake-2 carrier. Thus, 
only a small proportion of the uptic of &[‘sFlfluoro- 
tivity in the fd.Ma elements 
in the plasma. If this proportion applied 
decreases concent~tio~s 
c intravenous injection o 
ecreases myocardial 
derived ra~oact~v~ty i 
fluorodihydroxyphenylacetic acid n arterial p asma. 
The myocardial radioactivity concentration measured by 
PET scanning during or immediately after administration f 
6-[“8F]fluorodopamine, or the extent of change in that con- 
ct§ receiving the 3- to 
these doses woul 
the present study, by 
6-[ ‘8F]fluorodopamine, -60% of the injected compound was 
excreted into the urine. Thus, in humans, as in dogs (101, 
WI 
w~~~e k, is the physical decay constant 0.381R. ~~t~~ati~~ his 
a~~vity over the tim voiding, 3.39 h, to btain the c~rn~~at~ve 
activity A% (in mci- 
% 
-[(it - c- ~~~(k*k~~~ - ((1 - e- (IQ + k”‘)l(kr(kz + k&-J} = 0.476P0 
= 0. mCi-MllCi injected. 
For calcula~ $,, the cumulative activity due to I& by 3.31 h it 
could be assumed that ail the drug from the initial flush was excreted 
in the urine by 3.31 h. That is, from equation BT, B, = &, = 0.027pb. 
The amount of radioactivity due ta the drug from the initial flush is 
the bladder at that 
tts, assurrting that the subject voi& at 3.31 k but never again, 
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